Price History

Hover for the daily close. The dotted line marks the period open.

Compare EDVA with… →

EDVA Key Statistics

As of Sep 4, 2026

Trading

Open: $0.28
Previous Close: $0.27
Day's Range: 0.26–0.28
52-Week Range: 0.25–13.40
Volume: 70.20K
Beta: −1.09

Valuation

Market Cap: $1.83M
P/E Ratio: unprofitable
P/S ratio: 56.96
EPS (ttm): −45.04

Financials (FY)

Revenue (FY): $73.07K−90.88%
Net Income (FY): −$25.23M
Profit margin: 0.00%
Shares Outstanding: 6.92M
1-Year Return: −95.93%

Dividend and dates

Avg Volume: 4.56M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

EDVA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+66.67%+37.65%−66.72%−17.72%−42.56%−70.83%−89.29%−90.43%

2019*2020202120222023202420252026*

Year	Return
2026 (partial year)	−90.43%
2025	−89.29%
2024	−70.83%
2023	−42.56%
2022	−17.72%
2021	−66.72%
2020	+37.65%
2019 (partial year)	+66.67%

As of September 4, 2026.

EDVA Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$73.07K	−$25.23M	−34537.0%
2024	$801.27K	−$23.76M	−2964.9%
2023	$18.85M	−$21.00M	−111.4%
2022	$18.09M	−$21.69M	−119.9%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$73.07K	$16.90K	−$14.19M	−$25.23M	−34537.0%
2024	$801.27K	−$119.80K	−$9.90M	−$23.76M	−2964.9%
2023	$18.85M	$5.57M	−$15.29M	−$21.00M	−111.4%
2022	$18.09M	$5.92M	−$21.39M	−$21.69M	−119.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

EDVA Valuation vs Biotechnology Median

Median of 656 stocks

Metric	EDVA	Biotechnology median	vs median
P/S ratio	56.96	15.26	3.7x the median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Endovia Health Sciences, Inc. (EDVA) carries a market capitalisation of $1.83M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 1 employees.

EDVA last closed at $0.26 on September 4, 2026. That is −$0.01 (−1.86%) against the previous close. Over the past 52 weeks the price has ranged from $0.25 to $13.40. The latest close sits 5.6% above that 52-week low.

Financial Health

In fiscal 2025, Endovia Health Sciences, Inc. reported revenue of $73.07K. That is −90.88% against the prior fiscal year, when revenue was $801.27K. The same year closed with a net loss of $25.23M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −45.04.

Across the 4 fiscal years on file, revenue moves from $18.09M in 2022 to $73.07K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 56.96. On price-to-sales that is 3.7 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Over the trailing twelve months the price has returned −95.93%. Across 5 years the annualized return works out at −77.01%. The reported beta is −1.09. Daily returns over the trailing 7 years annualize to a volatility of 166.67%.

Growth & Income

The record shows no dividend for EDVA.

Across the complete calendar years on file, 2020 returned +37.65% and 2025 returned −89.29%. Of the 6 complete calendar years on file, 1 finished higher. So far in 2026 the price is −90.43%.

Peer Comparison

Endovia Health Sciences, Inc. (EDVA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Endovia Health Sciences, Inc.	EDVA	$1.83M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Endovia Health Sciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Endovia Health Sciences, Inc.

Endovia Health Sciences, Inc. engages in the manufacturing, distribution, marketing, and sale of various beverages in the United States. It operates in two segments Manufacture and Distribution of Non-Alcoholic and Alcoholic Beverages, and Retail Sale of Beverages and Groceries Online. The company offers flavored tequilas under the Chispo Tequila brand name; wine under the Copa DI Vino brand name; and sangria under the Pulpoloco Sangria brand name. It distributes its products through the business-to-business and business-to-consumer e-commerce distribution platform. The company was formerly known as Splash Beverage Group, Inc. and changed its name to Endovia Health Sciences, Inc. in August 2026. The company is based in Fort Lauderdale, Florida.

Visit website →

Endovia Health Sciences, Inc. (EDVA) Stock Analysis